What is FRC's Proprietary Fair Value Model?

FRC's Proprietary Fair Value Model is a premium feature that provides access to the same valuation methodology used by Fundamental Research Corp for allocating our firm's capital. This institutional-grade model combines fundamental analysis, financial modeling, and market metrics to determine a stock's intrinsic value. The model analyzes financial statements, earnings quality, growth rates, profitability ratios, and comparative valuations to calculate data-driven fair value estimates that professional investors trust for investment decisions. Available to premium subscribers.

What is Ipsen S.A. stock price today?

Ipsen S.A. (IPSEF) is currently trading at $185.93 USD on OTC. Get real-time price updates, Snowflake performance analysis, and comprehensive financial statements. Premium subscribers can access fair value analysis using FRC's proprietary valuation model.

What does Ipsen S.A. do?

Ipsen S.A. operates in the Medical - Pharmaceuticals sector within Healthcare. Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the trea...

How do I analyze Ipsen S.A. stock performance?

Our Snowflake Analysis provides a visual snapshot of Ipsen S.A. performance across 5 key metrics: Past Performance, Revenue Growth, Profitability, Value, and Financial Health. Each metric is scored 1-5, with 5 being excellent performance. This multi-dimensional view helps investors quickly assess stock quality and compare performance against peers.

Where can I find Ipsen S.A. financial statements?

Access Ipsen S.A. complete financial statements including income statement, balance sheet, and cash flow statement in our comprehensive stock profile. Our platform provides detailed financial ratios, trend analysis, and institutional-grade financial analysis used by professional investors.

What makes FRC's stock analysis different from other platforms?

FRC uses the same proprietary valuation model for public stock analysis that we use for allocating our own firm's capital. This means our fair value estimates are based on the same rigorous, data-driven methodology that institutional investors trust. Our analysis includes real-time pricing, Snowflake performance metrics, comprehensive financial modeling, and research reports from professional analysts - providing institutional-grade insights for individual investors.

About Ipsen S.A.

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

CEO

David Loew

Headquarters

65 Quai Georges Gorse, Boulogne-Billancourt, FR

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

CEO

David Loew

Headquarters

65 Quai Georges Gorse, Boulogne-Billancourt, FR

Description

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Ipsen S.A.

IPSEF•OTC

Ipsen S.A.

IPSEF•OTC

Market cap

$9.36B

Sentiment

Your view on IPSEF

Mkt Cap

$9.36B

Sentiment

Your view

Company Overview

Overview

What the company does, where it operates, and who runs it.

About Ipsen S.A.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
CEO: David Loew
Headquarters: 65 Quai Georges Gorse, Boulogne-Billancourt, FR

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
CEO: David Loew
Headquarters: 65 Quai Georges Gorse, Boulogne-Billancourt, FR

Description

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News